Discover the latest insights & resources from ROIS below
Articles
ROIS: The CDMO Making Waves in the US Market
The global CDMO market is forecast to double by 2032—yet specialist filling capacity remains a critical bottleneck for the industry. As demand for GLP-1s, biosimilars, and ADCs explodes, securing a partner with the right scale and regulatory pedigree on American soil is no longer just an operational need; it is a strategic imperative.
Explore why the Phoenix acquisition is a pivotal moment for ROIS, how it tackles the industry’s manufacturing bottleneck, and what this expansion means for your US-based programs.
Water for Injection: Why WFI Is Now a Strategic Manufacturing Decision
As biologics, vaccines, and high-value injectables drive demand, WFI has become a strategic constraint, with regulatory, cost, and operational implications that can delay or derail programs.
Explore why WFI is no longer an afterthought, when outsourcing makes sense, and what to consider when choosing a CDMO partner.
ROIS Reflects on 2025: Innovation, Investment and Global Growth
From major investments to global expansion, 2025 marked a defining year in ROIS’s continued evolution as a leading injectable CDMO.
CDMO Partnerships: Why Speed and Flexibility Matter Now More Than Ever
What used to be acceptable in 18 months, clients now want in 9 – with particular urgency for GLP-1s and biologics.
Scaling for the GLP-1 Revolution - Meeting Global Injectable Demand
It’s not just about being fast. It’s about being reliable and ready.
